The checklist is a decision sequence
Market analysis, fundraising and compliance are often treated as separate workstreams. For a physical product they are financially connected: classification changes the evidence required; evidence changes cost and time; cost and time change runway; and runway changes whether the market is investable now.
Work through the steps in order, but expect to loop back. If the route makes the initial product uneconomic, revise the product or the first market and test the decision again.
Define the exact product and intended use
Freeze the version you are assessing: materials, power source, connectivity, users, environment, claims, packaging and accessories. Small changes can move a product into a different regulatory route, so a vague ‘smart wellness device’ is not a usable starting point.
Evidence to keepA one-page product definition, intended-use statement and claims list.
Why investors careIt shows that the cost and launch date refer to a real configuration—not a moving concept.
Choose a first market, not ‘Europe’
The EU provides a common regulatory framework, but language, channels, price tolerance, competition, distribution and enforcement realities still vary. Select the first country using demand, margin, channel access and operational burden together.
Evidence to keepA country shortlist with the assumptions and rejection reasons recorded.
Why investors careA focused launch is easier to finance and test than a twenty-seven-country promise.
Validate demand before expensive compliance work
Use interviews, distributor conversations, landing-page tests and realistic price checks. Avoid taking pre-orders for a product whose legal route or delivery date is still unknown. The goal is evidence that buyers value this specific offer at a viable price.
Evidence to keepDemand signals tied to customer type, price and purchase context.
Why investors careIt separates genuine market evidence from interest generated by a prototype demo.
Map the likely regulatory route
Identify the frameworks triggered by product type, intended purpose, radio functions, software or AI, batteries, chemicals, users and claims. Record uncertainties explicitly. A route is useful only when it explains why requirements apply and what could change the conclusion.
Evidence to keepA provisional classification, applicable-framework map and uncertainty register.
Why investors careIt exposes binary risks—such as a medical claim—that can reset cost and timing.
Build the Regulatory Entry Budget
Include testing, technical documentation, specialists, translations, labels, authorised representation where needed, registrations and recurring obligations. Keep mandatory priced items separate from unpriced contingencies; a suspiciously precise single number hides uncertainty.
Evidence to keepA sourced low–high range, split into one-off and recurring costs.
Why investors careThe fundraising ask can include the real cost of becoming saleable, not only manufacturing and marketing.
Build the critical-path timeline
Sequence product freeze, supplier evidence, testing, corrective design work, documentation, labels and launch. Dependencies matter more than a list of durations. Add decision points for re-testing or classification escalation instead of assuming every activity succeeds first time.
Evidence to keepA dependency-based schedule with assumptions and contingency.
Why investors careIt connects cash runway to the first legally supportable revenue date.
Test unit economics after market-entry costs
Recalculate contribution margin after localisation, returns, representation, surveillance, channel fees and recurring compliance. Allocate one-off entry costs across a defensible sales volume and stress-test a slower launch.
Evidence to keepBase, downside and delayed-launch scenarios.
Why investors careIt reveals whether market access improves enterprise value or consumes capital without enough return.
Make and document the gate decision
Choose go, revise, wait or stop. State what evidence supports the decision, what remains uncertain and which conditions would trigger a review. A ‘revise’ decision may mean changing claims, features, launch country or product design—not abandoning the opportunity.
Evidence to keepA dated decision record with owners and next actions.
Why investors careIt demonstrates capital discipline and gives the next round a measurable plan.
What the final decision should contain
What to do next
Replace generic assumptions with your product’s numbers.
Regulatory Gate turns your product description, claims and intended use into an expert-reviewed view of likely route, cost range, timeline and the most consequential issue to resolve first.
Get my free Gate SnapshotReturn to Founder Hub